SG Americas Securities LLC grew its holdings in Haemonetics Corporation (NYSE:HAE - Free Report) by 510.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 10,580 shares of the medical instruments supplier's stock after acquiring an additional 8,848 shares during the period. SG Americas Securities LLC's holdings in Haemonetics were worth $672,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors have also modified their holdings of the business. Thrivent Financial for Lutherans grew its stake in shares of Haemonetics by 14.9% in the fourth quarter. Thrivent Financial for Lutherans now owns 1,264,294 shares of the medical instruments supplier's stock worth $98,716,000 after acquiring an additional 164,111 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Haemonetics by 1.1% during the 4th quarter. Dimensional Fund Advisors LP now owns 992,229 shares of the medical instruments supplier's stock worth $77,470,000 after purchasing an additional 10,990 shares during the last quarter. Fisher Asset Management LLC lifted its position in shares of Haemonetics by 3.2% during the 4th quarter. Fisher Asset Management LLC now owns 711,774 shares of the medical instruments supplier's stock worth $55,575,000 after purchasing an additional 22,265 shares during the last quarter. Northern Trust Corp lifted its position in shares of Haemonetics by 16.1% during the 4th quarter. Northern Trust Corp now owns 678,261 shares of the medical instruments supplier's stock worth $52,959,000 after purchasing an additional 93,848 shares during the last quarter. Finally, Silvercrest Asset Management Group LLC lifted its position in shares of Haemonetics by 31.0% during the 4th quarter. Silvercrest Asset Management Group LLC now owns 643,227 shares of the medical instruments supplier's stock worth $50,223,000 after purchasing an additional 152,042 shares during the last quarter. Institutional investors and hedge funds own 99.67% of the company's stock.
Haemonetics Stock Performance
HAE traded up $1.14 on Friday, reaching $71.20. The company had a trading volume of 662,869 shares, compared to its average volume of 679,766. Haemonetics Corporation has a 1 year low of $55.30 and a 1 year high of $94.99. The stock has a market capitalization of $3.42 billion, a PE ratio of 21.51, a P/E/G ratio of 1.15 and a beta of 0.36. The company has a quick ratio of 0.99, a current ratio of 1.62 and a debt-to-equity ratio of 1.12. The stock has a 50-day moving average price of $66.23 and a 200-day moving average price of $68.48.
Haemonetics (NYSE:HAE - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.24 earnings per share for the quarter, beating analysts' consensus estimates of $1.22 by $0.02. The firm had revenue of $330.60 million during the quarter, compared to analysts' expectations of $329.38 million. Haemonetics had a net margin of 12.32% and a return on equity of 26.37%. Haemonetics's quarterly revenue was down 3.5% compared to the same quarter last year. During the same period in the previous year, the company earned $0.90 earnings per share. As a group, research analysts forecast that Haemonetics Corporation will post 4.55 EPS for the current fiscal year.
Analyst Ratings Changes
Several equities research analysts have recently issued reports on the stock. Raymond James Financial reaffirmed a "strong-buy" rating and set a $105.00 price objective (down from $115.00) on shares of Haemonetics in a research report on Friday, May 9th. Wall Street Zen cut shares of Haemonetics from a "buy" rating to a "hold" rating in a research report on Tuesday, May 13th. JMP Securities reaffirmed a "market outperform" rating and set a $100.00 price objective on shares of Haemonetics in a research report on Tuesday, May 20th. Finally, Needham & Company LLC decreased their price objective on shares of Haemonetics from $104.00 to $84.00 and set a "buy" rating for the company in a research report on Thursday, May 8th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $97.89.
View Our Latest Report on Haemonetics
About Haemonetics
(
Free Report)
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.
Further Reading
Before you consider Haemonetics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haemonetics wasn't on the list.
While Haemonetics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
